We are committed to develop innovative solutions for bone regeneration in different application areas.
WHAT MAKES BIOCERAMED'S PRODUCTS DIFFERENT?
Calcium phosphate ceramics have been used as bone substitutes due to its similarity to the mineral part of the natural bone so that they can be recognized, dissolved and remodeled as new bone tissue. This synthetic bone graft substitutes are highly osteoconductive and bioactive, forming a strong bond to the host bone providing the adequate environment for the remodeling process. Calcium phosphate materials varying with chemistry have different dissolution rates and degradation rates. Generally speaking, dense hydroxyapatite (HA) is non-degradable or slowly degradable, tricalcium phosphate (TCP) is fast degradable or degradable, and biphasic calcium phosphates containing both HA and TCP are in between.
Bioceramed produces the HA and the biphasic mixtures of HA and TCP raw materials, used to incorporate in their products.
k-IBS® and Neocement® have also incorporated in their composition chitosan, a polysaccharide widely used in orthopedic treatment since it was shown to promote osteoblastic cell growth.
The biological properties of chitosan also include good biocompatibility and biodegradability as well as analgesic, hemostatic, antimicrobian and antioxidant properties. These properties come from the presence of amino groups that confers its positive (cationic) nature.
RESEARCH & DEVELOPMENT
We believe that being a knowledge-creator company contributes not only for the company’s collective success, but also for the personal growth of the individual.
Bioceramed continuously develops new solutions for bone regeneration and has contributed as active partner in several academic projects with several Universities and research institutes.
The CartHeal project (2018-2021) aims to contribute to the development of a new concept of hip prostheses with longer durability and containing drugs that will bring great benefits to patients: 1- Will reduce the need for revisions, 2- Will facilitate recovery in the postoperative, reducing systemic drug administration and consequent side effects.
This project aims to develop a theranostic system to prevent/treat infections associated with problematic wounds, namely in patients with compromised vascularization (such as diabetic patients) and wounds infected with multi-resistant microorganisms.
The STEReoSTRAT project (PTDC/CTM-BIO/3640/2014, start July 2016), supported by Fundação para a Ciência e a Tecnologia (FCT), aims to study the effect of conventional and new sterilization methods on the properties and performance of drug loaded hydrogels for biomedical applications. It involves the optimization of the sterilization procedures, as well as the modification of the hydrogels, in order to increase their resistance to eventual noxious effects of sterilization and guarantee an adequate drug release behavior.
The SurfLenses project (January 2014 – March 2017), supported by the European network M-ERA.NET, aimed to develop new efficient systems with controlled rate of drug-elution, for the treatment/prophylaxis of ocular diseases and post-surgical infections. Several strategies were followed, being given particular attention to the coating/surface modification of drug-loaded ophthalmic lens materials for soft contact lenses (SCLs) and intra ocular lenses IOLs.
The BIOHYBRID consortium (2011 - 2015) was build up with the overall aim to develop, in a preclinical perspective, an innovative device for the regenerative treatment of traumatic injuries of peripheral nerves. This consortium consists of three active and well integrated SMEs as well as six academic partners that are recognised leaders in the scientific areas of interest for this project.